Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 182

1.

Results, Knowledge, and Attitudes Regarding an Incentive Compensation Plan in a Hospital-Based, Academic, Employed Physician Multispecialty Group.

Dolan RW, Nesto R, Ellender S, Luccessi C.

J Healthc Manag. 2017 Mar/Apr;62(2):120-133. doi: 10.1097/JHM-D-17-00009.

PMID:
28282335
2.

SYNTAX Score and Long-Term Outcomes: The BARI-2D Trial.

Ikeno F, Brooks MM, Nakagawa K, Kim MK, Kaneda H, Mitsutake Y, Vlachos HA, Schwartz L, Frye RL, Kelsey SF, Waseda K, Hlatky MA; BARI-2D Study Group.

J Am Coll Cardiol. 2017 Jan 31;69(4):395-403. doi: 10.1016/j.jacc.2016.10.067.

PMID:
28126156
3.

Evaluation of lorcaserin on progression of prediabetes to type 2 diabetes and reversion to euglycemia.

Nesto R, Fain R, Li Y, Shanahan W.

Postgrad Med. 2016 May;128(4):364-70. doi: 10.1080/00325481.2016.1178590.

PMID:
27116910
4.

Pioglitazone after Ischemic Stroke or Transient Ischemic Attack.

Kernan WN, Viscoli CM, Furie KL, Young LH, Inzucchi SE, Gorman M, Guarino PD, Lovejoy AM, Peduzzi PN, Conwit R, Brass LM, Schwartz GG, Adams HP Jr, Berger L, Carolei A, Clark W, Coull B, Ford GA, Kleindorfer D, O'Leary JR, Parsons MW, Ringleb P, Sen S, Spence JD, Tanne D, Wang D, Winder TR; IRIS Trial Investigators.

N Engl J Med. 2016 Apr 7;374(14):1321-31. doi: 10.1056/NEJMoa1506930. Epub 2016 Feb 17.

5.

Troponin and Cardiac Events in Stable Ischemic Heart Disease and Diabetes.

Everett BM, Brooks MM, Vlachos HE, Chaitman BR, Frye RL, Bhatt DL; BARI 2D Study Group.

N Engl J Med. 2015 Aug 13;373(7):610-20. doi: 10.1056/NEJMoa1415921.

6.

Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus.

Scirica BM, Bhatt DL, Braunwald E, Steg PG, Davidson J, Hirshberg B, Ohman P, Frederich R, Wiviott SD, Hoffman EB, Cavender MA, Udell JA, Desai NR, Mosenzon O, McGuire DK, Ray KK, Leiter LA, Raz I; SAVOR-TIMI 53 Steering Committee and Investigators.

N Engl J Med. 2013 Oct 3;369(14):1317-26. doi: 10.1056/NEJMoa1307684. Epub 2013 Sep 2.

7.

Individualized glycaemic targets and pharmacotherapy in type 2 diabetes.

Bailey CJ, Aschner P, Del Prato S, LaSalle J, Ji L, Matthaei S; Global Partnership for Effective Diabetes Management.

Diab Vasc Dis Res. 2013 Sep;10(5):397-409. doi: 10.1177/1479164113490765. Epub 2013 May 27. Review.

PMID:
23711582
8.

Strategies for multivessel revascularization in patients with diabetes.

Farkouh ME, Domanski M, Sleeper LA, Siami FS, Dangas G, Mack M, Yang M, Cohen DJ, Rosenberg Y, Solomon SD, Desai AS, Gersh BJ, Magnuson EA, Lansky A, Boineau R, Weinberger J, Ramanathan K, Sousa JE, Rankin J, Bhargava B, Buse J, Hueb W, Smith CR, Muratov V, Bansilal S, King S 3rd, Bertrand M, Fuster V; FREEDOM Trial Investigators.

N Engl J Med. 2012 Dec 20;367(25):2375-84. doi: 10.1056/NEJMoa1211585. Epub 2012 Nov 4.

9.

Clinical and angiographic risk stratification and differential impact on treatment outcomes in the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) trial.

Brooks MM, Chaitman BR, Nesto RW, Hardison RM, Feit F, Gersh BJ, Krone RJ, Sako EY, Rogers WJ, Garber AJ, King SB 3rd, Davidson CJ, Ikeno F, Frye RL; BARI 2D Study Group.

Circulation. 2012 Oct 23;126(17):2115-24. doi: 10.1161/CIRCULATIONAHA.112.092973. Epub 2012 Sep 24.

10.

Glucose-insulin-potassium for suspected acute myocardial infarction.

Chaudhuri A, Nesto R, Dandona P.

JAMA. 2012 Sep 5;308(9):859; author reply 859-60. doi: 10.1001/jama.2012.9768. No abstract available.

PMID:
22948688
11.

Direct comparison of Takotsubo cardiomyopathy between Japan and USA: 3-year follow-up study.

Maekawa Y, Kawamura A, Yuasa S, Nesto RW, Fukuda K.

Intern Med. 2012;51(3):257-62. Epub 2012 Feb 1.

12.

Presentation in patients with angiographically documented coronary artery disease and type II diabetes mellitus (from the BARI 2D Clinical Trial).

Krishnaswami A, Hardison R, Nesto RW, Sobel B; BARI 2D Investigators.

Am J Cardiol. 2012 Jan 1;109(1):36-41. doi: 10.1016/j.amjcard.2011.08.004. Epub 2011 Sep 28.

PMID:
21958742
13.

Blood pressure, lipids and glucose in type 2 diabetes: how low should we go? Re-discovering personalized care.

Rutter MK, Nesto RW.

Eur Heart J. 2011 Sep;32(18):2247-55. doi: 10.1093/eurheartj/ehr154. Epub 2011 Jun 23. Review.

PMID:
21705358
15.

Evaluation of in-stent restenosis in the APPROACH trial (Assessment on the Prevention of Progression by Rosiglitazone On Atherosclerosis in diabetes patients with Cardiovascular History).

García-García HM, Garg S, Brugaletta S, Morocutti G, Ratner RE, Kolatkar NS, Kravitz BG, Miller DM, Huang C, Nesto RW, Serruys PW; APPROACH study group.

Int J Cardiovasc Imaging. 2012 Mar;28(3):455-65. doi: 10.1007/s10554-011-9836-z. Epub 2011 Feb 27.

16.
17.

The prevalence and predictors of an abnormal ankle-brachial index in the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) trial.

Singh PP, Abbott JD, Lombardero MS, Sutton-Tyrrell K, Woodhead G, Venkitachalam L, Tsapatsaris NP, Piemonte TC, Lago RM, Rutter MK, Nesto RW; Bypass Angioplasty Revascularization Investigation 2 Diabetes Study Group.

Diabetes Care. 2011 Feb;34(2):464-7. doi: 10.2337/dc10-1734.

19.

Coronary revascularisation in the patient with diabetes: balancing risk and benefit.

Rutter MK, Nesto RW.

Heart. 2010 Sep;96(18):1436-40. doi: 10.1136/hrt.2010.201541. Review. No abstract available.

PMID:
20813726
20.

National Kidney Foundation consensus conference on cardiovascular and kidney diseases and diabetes risk: an integrated therapeutic approach to reduce events.

Bakris G, Vassalotti J, Ritz E, Wanner C, Stergiou G, Molitch M, Nesto R, Kaysen GA, Sowers JR; CKD Consensus Working Group.

Kidney Int. 2010 Oct;78(8):726-36. doi: 10.1038/ki.2010.292. Epub 2010 Aug 18.

Supplemental Content

Loading ...
Support Center